首页> 外文期刊>Stroke: A Journal of Cerebral Circulation >RAPID automated patient selection for reperfusion therapy: a pooled analysis of the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) and the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) Study.
【24h】

RAPID automated patient selection for reperfusion therapy: a pooled analysis of the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) and the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) Study.

机译:RAPID自动选择患者进行再灌注治疗:超声平面成像溶栓评估试验(EPITHET)和扩散与灌注成像评估的综合分析,以了解中风演变(DEFUSE)研究。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND PURPOSE: The aim of this study was to determine if automated MRI analysis software (RAPID) can be used to identify patients with stroke in whom reperfusion is associated with an increased chance of good outcome. METHODS: Baseline diffusion- and perfusion-weighted MRI scans from the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution study (DEFUSE; n=74) and the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET; n=100) were reprocessed with RAPID. Based on RAPID-generated diffusion-weighted imaging and perfusion-weighted imaging lesion volumes, patients were categorized according to 3 prespecified MRI profiles that were hypothesized to predict benefit (Target Mismatch), harm (Malignant), and no effect (No Mismatch) from reperfusion. Favorable clinical response was defined as a National Institutes of Health Stroke Scale score of 0 to 1 or a >/= 8-point improvement on the National Institutes of Health Stroke Scale score at Day 90. RESULTS: In Target Mismatch patients, reperfusion was strongly associated with a favorable clinical response (OR, 5.6; 95% CI, 2.1 to 15.3) and attenuation of infarct growth (10 +/- 23 mL with reperfusion versus 40 +/- 44 mL without reperfusion; P<0.001). In Malignant profile patients, reperfusion was not associated with a favorable clinical response (OR, 0.74; 95% CI, 0.1 to 5.8) or attenuation of infarct growth (85 +/- 74 mL with reperfusion versus 95 +/- 79 mL without reperfusion; P=0.7). Reperfusion was also not associated with a favorable clinical response (OR, 1.05; 95% CI, 0.1 to 9.4) or attenuation of lesion growth (10 +/- 15 mL with reperfusion versus 17 +/- 30 mL without reperfusion; P=0.9) in No Mismatch patients. CONCLUSIONS: MRI profiles that are associated with a differential response to reperfusion can be identified with RAPID. This supports the use of automated image analysis software such as RAPID for patient selection in acute stroke trials.
机译:背景与目的:这项研究的目的是确定是否可以使用自动MRI分析软件(RAPID)来识别中风患者,其再灌注与良好结果的机会增加相关。方法:使用RAPID对来自弥散和灌注成像评估以了解卒中发展研究(DEFUSE; n = 74)和回声成像溶栓评估试验(EPITHET; n = 100)的基线弥散和灌注加权MRI扫描进行重新处理。基于RAPID生成的弥散加权成像和灌注加权成像病变体积,根据3种预先指定的MRI图像对患者进行分类,这些MRI图像可预测患者的获益(靶点不匹配),伤害(恶性)和无效(无错配)再灌注。良好的临床反应被定义为美国国立卫生研究院卒中量表评分为0到1或国立卫生研究院卒中量表评分在第90天提高了> / = 8点。结果:在靶位不匹配患者中,再灌注强烈与良好的临床反应(OR,5.6; 95%CI,2.1至15.3)和梗死生长减慢(有再灌注的10 +/- 23 mL与没有再灌注的40 +/- 44 mL; P <0.001)相关。在恶性肿瘤患者中,再灌注与良好的临床反应(OR,0.74; 95%CI,0.1至5.8)或梗塞生长减慢(再灌注为85 +/- 74 mL,未再灌注为95 +/- 79 mL)无关。 ; P = 0.7)。再灌注也与良好的临床反应(OR,1.05; 95%CI,0.1至9.4)或病灶生长减慢(再灌注为10 +/- 15 mL,未再灌注为17 +/- 30 mL)无关; P = 0.9 )在没有错配的患者中。结论:可以用RAPID识别与对再灌注的不同反应相关的MRI图。这支持在急性卒中试验中使用自动图像分析软件(例如RAPID)来选择患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号